- Trials with a EudraCT protocol (6,129)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (7)
6,129 result(s) found for: Death.
Displaying page 1 of 307.
EudraCT Number: 2023-000010-18 | Sponsor Protocol Number: WATERLAND | Start Date*: 2023-03-23 | |||||||||||
Sponsor Name:Enrique de Madaria | |||||||||||||
Full Title: Normal saline versus lactated Ringer’s solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002644-32 | Sponsor Protocol Number: EFC14875 | Start Date*: 2017-11-14 | ||||||||||||||||
Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes, Ca... | ||||||||||||||||||
Medical condition: Type 2 diabetes mellitus Chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Prematurely Ended) LV (Completed) GB (Completed) HU (Completed) SE (Completed) NO (Completed) FR (Completed) NL (Completed) DK (Completed) ES (Prematurely Ended) LT (Completed) EE (Completed) PT (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000305-13 | Sponsor Protocol Number: RIVAROXDVT3002/BAY59-7939/17261 | Start Date*: 2014-07-07 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) | |||||||||||||
Medical condition: Prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill patients. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) HU (Completed) CZ (Completed) IT (Completed) ES (Completed) NL (Completed) LT (Completed) BG (Completed) GR (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) SK (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003510-16 | Sponsor Protocol Number: EFC15156 | Start Date*: 2018-05-07 | ||||||||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabet... | ||||||||||||||||||
Medical condition: Cardiovascular diseases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) NL (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) GB (Completed) BE (Completed) DK (Prematurely Ended) FR (Completed) AT (Completed) CZ (Prematurely Ended) DE (Completed) SK (Completed) HU (Completed) FI (Completed) PT (Completed) GR (Completed) PL (Completed) IE (Completed) IT (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000779-26 | Sponsor Protocol Number: ECABUSCA12 | Start Date*: 2014-08-19 |
Sponsor Name:Asociación Instituto Biodonostia | ||
Full Title: Efficacy of subcutaneous butylscopolamine vs placebo for control to death rattle in agony. Randomized clinical trial. | ||
Medical condition: phase of agony, pre-death | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003519-23 | Sponsor Protocol Number: D513BC00001 | Start Date*: 2014-02-05 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Pat... | ||||||||||||||||||
Medical condition: major cardiovascular events in type 2 diabetes mellitus patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) NL (Completed) DE (Completed) IT (Completed) GB (Completed) ES (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) FI (Completed) BG (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002942-12 | Sponsor Protocol Number: P04737 | Start Date*: 2007-10-22 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis... | |||||||||||||
Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000802-46 | Sponsor Protocol Number: D169CC00001 | Start Date*: 2018-09-24 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur... | ||
Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2007-004369-16 | Sponsor Protocol Number: MJ/LPGB/12/2006 | Start Date*: 2007-11-29 |
Sponsor Name:St Raphael's Hospice, Surrey | ||
Full Title: ''Evaluation of the efficacy of 'TRANS-DERMAL NITRATE' in reducing the severity of 'death-rattle' (i.e 'terminal lung secretions' ) in patients dying from end stage malignancy'' | ||
Medical condition: 'Death-rattle' (i.e 'terminal lung secretions') in adult patients dying from end-stage malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005960-68 | Sponsor Protocol Number: D9319C00001 | Start Date*: 2021-07-24 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioi... | ||
Medical condition: Olaparib Maintenance Monotherapy in Participants with BRCAWild Type Ovarian Cancer Following Response toFirst-line Platinum-based Chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000664-31 | Sponsor Protocol Number: D169DC00001 | Start Date*: 2020-08-12 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac... | ||
Medical condition: Acute Myocardial Infarction, Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2013-001498-25 | Sponsor Protocol Number: CRLX030A2301 | Start Date*: 2013-09-09 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure pa... | ||
Medical condition: Acute heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) BE (Completed) SE (Completed) IE (Completed) BG (Completed) HU (Completed) PT (Completed) LT (Prematurely Ended) IT (Completed) CZ (Completed) AT (Completed) EE (Completed) DK (Completed) ES (Completed) LV (Prematurely Ended) NL (Completed) GR (Completed) GB (Completed) PL (Completed) NO (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004160-58 | Sponsor Protocol Number: CHASAP | Start Date*: 2021-06-11 | ||||||||||||||||
Sponsor Name:Centre hospitalier intercommunal de Créteil | ||||||||||||||||||
Full Title: Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a multicenter prospective randomized double-blind placebo-controlled trial | ||||||||||||||||||
Medical condition: Pregnant women with chronic hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000671-25 | Sponsor Protocol Number: 1242-001 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S... | |||||||||||||
Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002287-14 | Sponsor Protocol Number: Reutelen | Start Date*: 2016-12-23 | |||||||||||
Sponsor Name:Erasmus MC Cancer Institute | |||||||||||||
Full Title: Death rattle in the dying phase: is prophylactic treatment useful? | |||||||||||||
Medical condition: Death rattle in the dying phase | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003201-26 | Sponsor Protocol Number: 1160.186 | Start Date*: 2014-07-21 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim AB | ||||||||||||||||||
Full Title: A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. tr... | ||||||||||||||||||
Medical condition: Patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) DK (Completed) GR (Completed) DE (Completed) PT (Completed) HU (Completed) ES (Completed) FI (Completed) NL (Completed) CZ (Completed) AT (Completed) IT (Completed) BE (Completed) IE (Completed) SK (Completed) SI (Completed) GB (Completed) BG (Completed) HR (Completed) PL (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004616-36 | Sponsor Protocol Number: D5135C00001 | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic str... | |||||||||||||
Medical condition: peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) NL (Completed) PL (Completed) GB (Completed) SE (Completed) ES (Completed) DE (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000996-98 | Sponsor Protocol Number: CSL112_3001 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome | |||||||||||||
Medical condition: Acute Coronary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001384-23 | Sponsor Protocol Number: REG1-CLIN310 | Start Date*: 2013-10-30 | |||||||||||
Sponsor Name:Regado Biosciences, Inc. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF THE REG1 ANTICOAGULATION SYSTEM COMPARED TO BIVALIRUDIN IN PATIENTS UNDERGOIN... | |||||||||||||
Medical condition: Coronary Artery Disease (CAD) in patients undergoing Percutaneous Coronary Intervention (PCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended) NL (Completed) PT (Prematurely Ended) AT (Completed) GB (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004112-60 | Sponsor Protocol Number: D9311C00001 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or with... | |||||||||||||
Medical condition: Endometrial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) GR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
